Raltitrexed and Oxaliplatin for Pancreatic Cancer
Author Information
Author(s): Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes A A
Primary Institution: S. Raffaele Hsc. Scientific Inst.
Hypothesis
Can raltitrexed and oxaliplatin improve outcomes in gemcitabine-resistant metastatic pancreatic cancer?
Conclusion
The raltitrexed-oxaliplatin regimen may provide a treatment opportunity for patients with gemcitabine-resistant metastatic pancreatic cancer.
Supporting Evidence
- 10 patients (24%) had a partial response to treatment.
- Median survival was 5.2 months.
- Progression-free survival at 6 months was 14.6%.
- Quality of life improved in numerous domains.
Takeaway
This study tested a new combination of drugs for patients whose cancer didn't respond to standard treatment, and it showed some patients got better.
Methodology
Patients received raltitrexed and oxaliplatin every 3 weeks until disease progression or unacceptable toxicity.
Potential Biases
Potential selection bias due to the specific inclusion criteria for prior treatments.
Limitations
The study had a small sample size and was limited to patients with specific prior treatment histories.
Participant Demographics
{"age":{"median":61,"range":"25-80"},"sex":{"male":23,"female":18},"performance_status":{"70-80":16,"90-100":25}}
Statistical Information
P-Value
0.006
Confidence Interval
{"response_rate":"95% CI 11–37%","median_survival":"95% CI 2.2–22.2%"}
Statistical Significance
p=0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website